This medication is generally used across therapeutic domains where short-term symptomatic assistance is needed. The medication is generally relevant for addressing conditions that involve symptomatic discomfort, including those related to atrophic vaginitis and flora restoration.

---

Relief from Vaginal Dryness and Atrophy Symptoms

The medication is commonly used in conditions presenting with symptoms related to physical discomfort. It helps address symptom clusters that may become intense or disruptive, such as persistent vaginal dryness, burning, and pain during sexual activity (dyspareunia). This therapeutic approach provides support that contributes to easing the overall symptom load and helps improve day-to-day comfort. The medication is relevant in clinical settings that involve acute or unstable symptom patterns.

---

Restoration of Vaginal Flora and Imbalance Management

The medication is also applied in contexts where additional management of discomfort is required in situations involving episodic or fluctuating manifestations. It is relevant when supportive symptom management is appropriate to manage recurrent or episodic manifestations of microbial imbalance. This treatment is applied in conditions where functional stability becomes affected, and provides support that helps ease the overall symptom burden, contributing to better day-to-day comfort.

---

“It is applied across domains where additional symptomatic support is needed to address discomfort and aid in restoration.”

---

Quick Fact: Relief for Atrophy Symptoms and Flora Imbalance The medication is commonly used across conditions presenting with episodic or fluctuating symptom patterns.

Regulatory References

1. FDA Philippines Professional Information on Lactobacillus Acidophilus + Estriol

Eligibility Map: Who can and cannot use Гинофлор — official regulatory information

---

Eligibility Scope

Populations for whom use is allowed (as stated in label): Adult women and adolescent girls who have experienced menarche.

Populations for whom use is contraindicated: Individuals with known hypersensitivity to the active ingredients or excipients; those with existing, suspected, or a history of estrogen-dependent malignancies (e.g., breast or endometrial cancer); patients with endometriosis or untreated endometrial hyperplasia; and those with unexplained genital bleeding. The medicine is strictly contraindicated for girls before menarche, in cases of severe hepatic insufficiency, and for those with a history of blood clots or thromboembolic disorders.

Age-related eligibility rules: Use is prohibited before menarche. The standard adult dose is recommended for post-menarche adolescents, and no age-related dose adjustment is necessary for older adults.

Pregnancy and lactation eligibility status: Use during pregnancy requires a careful medical assessment of risks and benefits; caution is advised during the first trimester. The medicine may be used while breastfeeding.

Eligibility-related restrictions: Use requires caution and monitoring in patients with severe impairment of renal or cardiac function, as well as those with certain systemic conditions including diabetes mellitus, hypertension, epilepsy, or hyperlipidaemia.

---

Eligibility Classifications (High-Level)

Eligibility severity classification: Categorized as Contraindicated (absolute prohibition), Conditional/Caution (use only with close medical oversight), and Allowed (standard use in eligible populations).

Regulatory basis: Eligibility information is based on official government regulatory documents, including Professional Information from national health authorities.

Eligibility-context constraints: Eligibility is primarily constrained by risks associated with the estriol component and developmental status.

Interactions with other medicines and products

Regulatory documentation focuses on the potential for local drug interactions that compromise the viability of the Lactobacillus acidophilus component.

Documented Interaction Patterns

• Pharmacodynamic Interaction: The efficacy of the vaginal tablet may be reduced by the co-administration of local or systemic anti-infective agents, such as antibiotics or antifungals. This effect is a result of the anti-infective agent inhibiting the essential bacterial culture.
• Administration Restriction: Simultaneous treatment with anti-infective agents, as well as the concurrent use of any other intravaginal products, must be strictly avoided.

Systemic and Population Considerations

Classification	Regulatory Statement
Systemic PK Interactions	Clinically relevant interactions with other systemic medicinal products are not expected due to the very low estriol content and topical administration.
Population-Specific Note	Close monitoring may be required for patients with severe renal insufficiency due to the potential for increased estriol plasma levels.

This interaction profile is characterized by the need to maintain the microbial integrity of the formulation. The lack of documented systemic pharmacokinetic interactions reflects the minimal and transient absorption of the estriol component, consistent with official prescribing information.

The pharmacological action of Гинофлор is defined by a precisely coordinated, dual-target mechanism that acts on both the tissue structure and the biochemical environment of the vaginal ecosystem.

The Estriol ( E3) component acts as an agonist on local Estrogen Receptors within the vaginal epithelial cell nuclei, initiating gene transcription that drives cell proliferation and maturation. This hormonal action causes the epithelial cells to significantly increase their internal synthesis and storage of Glycogen, a vital carbohydrate that serves as the exclusive metabolic fuel source for the introduced bacteria.

The introduced, viable Lactobacillus acidophilus (KS400) strains rapidly colonize the tissue, utilizing the Estriol-induced Glycogen via fermentation to produce large quantities of Lactic Acid. This metabolic process results in a rapid and sustained reduction of the ambient pH to a highly acidic range (sim 3.8-4.5). This low pH creates a local environment that restricts the growth and adhesion of most acid-intolerant non-indigenous microorganisms.

The two mechanisms are functionally interdependent, creating a system that supports Lactobacillus dominance. The hormonal action creates the essential metabolic terrain (glycogen supply) that enables the bacterial component to function optimally, while the resulting pH reduction contributes to the dominance of the introduced Lactobacillus strains. This synergy establishes an environment supporting the dominance of Lactobacillus by simultaneously influencing the tissue barrier structure and the biochemical environment.

The administration of Гинофлор is limited to the local intravaginal route using the available dosage form: the vaginal tablet, which delivers 1 imes 10^8 cfu of Lactobacillus acidophilus and 0.03 mg of Estriol. The administration protocol follows a dual-phase schedule.

Initial Treatment and Maintenance

The treatment begins with the initial phase, which involves the use of one tablet once daily for a continuous course that typically spans 6 to 12 days. Following the completion of this daily course, the regimen is modified to a maintenance schedule, where the dose remains one tablet but is applied intermittently, usually on two to three separate days per week.

Procedural and Contextual Requirements

For use, the tablet is inserted deeply into the vagina. Administration is performed in the evening before retiring (at bedtime) to ensure retention and localization of the active components throughout the night. The procedure involves the patient being in a reclining position with the knees slightly bent. If the vaginal area is extremely dry, the tablet may be briefly moistened with a small amount of water to assist with insertion and the initiation of dissolution. Regarding population-specific details, the adult dose is applicable to adolescents who have reached menarche, and no dose adjustment is necessary for older adults.

Research evidence / Overview of studies for Гинофлор

Evidence for Symptomatic Vaginal Atrophy (GSM)

Research has explored the use of this medicine in conditions characterized by fluctuating or episodic manifestations of low-estrogen states, often referred to as symptomatic vaginal atrophy or Genitourinary Syndrome of Menopause (GSM). Studies conducted during periods of increased symptom activity include double-blind, randomized controlled trials (RCTs) and follow-up studies. These research examined specific outcomes related to physical discomfort, such as patient-reported scores for dryness, burning, and pain during sexual activity (dyspareunia). They also monitored physiological outcomes, including changes in the vaginal pH and the epithelial health, which is measured using tools like the Vaginal Maturation Index (VMI).

Studies reported measurements of VMI scores, with findings describing patterns observed in the studied populations compared to control groups at short-term follow-up intervals. Research highlights changes in pH measured during the study period, with some trials reporting patterns consistent with shifts toward the acidic range. Data for long-term outcomes, particularly concerning the maintenance of epithelial changes, are still emerging and require broader confirmation across larger studies.

Evidence for Restoring Disturbed Vaginal Flora

Research utilized randomized controlled trials (RCTs) focusing on outcomes related to systemic or functional imbalance, and included study populations following anti-infective therapy or with conditions associated with abnormal vaginal flora, such as Bacterial Vaginosis. The studies were designed to evaluate the microbial status of the vaginal environment, specifically measuring the change in lactobacillary grade and the quantitative presence of Lactobacillus acidophilus.

Studies reported measurements where findings describe patterns observed in the studies, including the measurement of increased abundance of Lactobacillus species in the observed populations following the short-term evaluation period. Clinical data show patterns related to the measured changes in microbial imbalance based on microscopic criteria in some studied participants. There is limited information for long-term outcomes regarding the prevention of recurrence of these conditions.

Summary of Evidence Gaps

The overall evidence for some applications is considered limited. The evidence quality varies across studies, and long-term effects are not fully established across the spectrum of studied conditions. A key limitation is that sample sizes were modest in several initial trials. Furthermore, data for certain groups, such as postmenopausal women with breast cancer receiving aromatase inhibitor therapy, were evaluated in specific research. The existing study results reflect the specific conditions under which they were conducted, providing context but not individual predictions.

Common questions about Гинофлор (FAQ)

---

Q: Do the beneficial effects of Гинофлор continue after the course of treatment is finished?

Official product information indicates that an initial daily treatment course is usually followed by a maintenance schedule. This intermittent maintenance use is generally put in place to help prevent the relapse of symptoms associated with conditions like vaginal atrophy. The aim of this maintenance phase is to support the continued stability of the vaginal environment.

---

Q: What is the general information on the long-term safety profile of using Гинофлор repeatedly?

Regulatory information indicates that the medicine is applied locally and contains a very low amount of estriol, meaning systemic interactions are considered unlikely. However, the available data on the safety profile for repeated or prolonged use over many years is not fully established and continues to be evaluated.

---

Q: Why do some users report increased discharge or residue after using the tablet?

It is common to find tablet remains or experience increased discharge after administration. This occurs because the tablet contains non-active ingredients (excipients) that may not dissolve completely. Official sources confirm that the presence of this residue does not affect the efficacy of the medicine.

---

Q: How does the concentration of estriol in Гинофлор compare to that in systemic hormone replacement therapy?

The estriol component is an ultra-low dose (0.03 mg), which is significantly lower than that found in conventional vaginal estrogen preparations. Official pharmacokinetic data shows that this ultra-low dose results in a very small, transient increase in estriol levels, and minimal systemic absorption is generally observed.

---

Q: Is it common for the tablet to feel like it has not fully dissolved after application?

Official instructions and safety information confirm that it is common for the tablet to feel like it has not fully dissolved. Tablet remains may occasionally be found after administration because the excipients (non-active ingredients) do not dissolve completely.

---

Q: How are the active components of Гинофлор absorbed by the body?

The medicine is designed for local action. The Lactobacillus acidophilus component works by colonizing the vaginal area to create a protective, acidic environment. The estriol component is absorbed primarily to mature the vaginal lining locally, with only a small, short-lived amount entering the rest of the body.

---

Q: How is Гинофлор different from regular oral probiotics?

Гинофлор is classified as a combined gynecological product containing both a hormone (estriol) and a probiotic (Lactobacillus), and it is administered locally in the vagina. This dual-active, local approach to restoring both tissue health and microbial balance distinguishes it from oral probiotics, which are typically designed to target the gut.

---

Q: Is Гинофлор considered a hormone replacement therapy?

While the medicine contains the estrogen hormone estriol, it is classified as a local estrogen preparation due to its ultra-low dose and topical administration. Because systemic effects are considered very unlikely, it is distinguished from higher-dose systemic Hormone Replacement Therapy (HRT) used for general menopausal symptoms.

---

Q: How quickly do users typically report feeling relief after starting Гинофлор?

Studies have examined the physiological effects of the medicine and show that physiological changes, such as improvements in the vaginal lining measured by tools like the Vaginal Maturation Index (VMI), begin to be observed during the initial treatment course.

---

Q: Is there any official guidance regarding the use of Гинофлор during menstruation?

Official guidance on using the medicine during a period indicates that treatment is typically interrupted during menstruation and then resumed afterwards.

---

Q: Does Гинофлор have known interactions with common forms of hormonal birth control?

Regulatory information indicates that clinically relevant interactions with systemic medicinal products, including hormonal contraceptives, are considered unlikely. This is due to the product's very low estriol content and its topical administration route.

---

Q: What is the advised course of action if a dose of Гинофлор is forgotten?

If a dose is missed, official patient information describes that it may be applied as soon as the lapse is remembered. If it is already very close to the time for the next scheduled dose, the missed dose is usually skipped. Dosing information typically indicates that doubling the dose is not recommended.

---

Q: Is Гинофлор available only by prescription in most countries, or is it over-the-counter?

According to official product details, Гинофлор is classified as a medicinal product subject to medical prescription. It is not available for purchase over-the-counter.

---

Q: Does Гинофлор contain any non-active ingredients that could be problematic for common allergies?

The tablet contains several non-active ingredients, or excipients, including Lactose monohydrate and magnesium stearate. Official contraindication statements describe that use is prohibited if a person has a known hypersensitivity or allergy to the active substances or any of the excipients.

---

Q: When is the medicine usually recommended by healthcare professionals?

The medicine is authorized for use in specific contexts: it is indicated for the restoration of vaginal flora after a course of local or systemic anti-infective treatment. It is also authorized for the treatment of atrophic vaginitis (GSM) in postmenopausal or perimenopausal women.

How to Store and Dispose of Гинофлор (Gynoflor)

The storage requirements for Гинофлор are designed to maintain the integrity of its live bacterial culture, requiring cold temperatures.

Storage Conditions

The medicine must be stored in a refrigerator at a temperature range of 2 °C to 8 °C; the product should not be frozen. The tablets must be kept in their blister strip and the outer carton to protect them from light and environmental damage.

Regulatory information permits temporary storage at room temperature for a period of one to two weeks without affecting efficacy. The medicine must be kept out of the sight and reach of children and should not be used past the expiry date.

Disposal

To dispose of unused or expired product, do not flush the medicine down toilets or dispose of it in drains. All unused Гинофлор must be returned to your pharmacist for appropriate disposal.